Translation and psychometric properties of the King’s Sarcoidosis Questionnaire (KSQ) in German language

Erik Farin 1*, Katja Heyduck 1, Björn Christian Frye 2, Surinder S. Birring 3, Joachim Müller-Quernheim 2 and Jonas Christian Schupp 2,4

Abstract

Background: King’s Sarcoidosis Questionnaire (KSQ) is a novel, validated, health-related quality of life questionnaire on sarcoidosis with 5 scales and 29 items. For future multinational observational and interventional studies on sarcoidosis, a validated German version of the KSQ is needed. The objective of our study is to translate the original KSQ and develop a German version possessing good psychometric properties and with as few modifications as possible.

Methods: We translated the KSQ into German, tested it in structured interviews in sarcoidosis patients, and asked consecutive patients in an outpatient clinic to complete it. We relied on the KSQ’s original version to achieve its psychometric properties in the German version. Structural validity, internal consistency, construct validity, and fit to Rasch model were assessed. Our procedure’s logic meant that in the first step we optimized the item selection in the German version to maximize its psychometric quality. In step two, we assessed the unmodified version’s properties in comparison to the modified version’s.

Results: One hundred ninety-four patients with sarcoidosis were included and completed the questionnaires. Due to ambiguous factor loadings, four items of the scale “General Health Status” had to be eliminated. Another item was excluded to ensure the Rasch model fit. This modified, 24-item version of the KSQ shows acceptable Rasch model fit and good model fit in confirmatory factor analyses (TLI = 0.90, CFI = 0.91, RMSEA = 0.08). Cronbach’s Alpha ranges from 0.82 to 0.91. Several hypotheses concerning construct validity (e.g., correlations with SF-36) are confirmed or partly confirmed. The measurement properties of the original unmodified version are similar in their construct validity and internal consistency; however, we were unable to confirm structural validity and fit to the Rasch model in the original version.

Conclusions: We translated and validated the German KSQ and report good psychometric properties. The reduced 24-item version has the advantage that all scales are unidimensional and fulfil the requirements of the Rasch model, ensuring its benefits. The original 29-item version, on the other hand, allows us to compare German data to international data however, at the price, of less structural validity and the lack of fit to the Rasch model.

Trial registration: This study was registered in the German Clinical Trials Register (reference number DRKS00010072). Registered January 2016.

Keywords: Sarcoidosis, Questionnaire, German, Quality of life, Human
Background
Sarcoidosis is a systemic granulomatous disease most often affecting the lung, the lymph nodes, the eyes, and the skin [1, 2]. Patients with sarcoidosis may suffer from pulmonary symptoms such as cough, dyspnea or chest pain, or systemic symptoms such as fever, weight loss or night sweat. Therefore, sarcoid patients often suffer poorer general health and lower respiratory-specific quality of life [3, 4].

Clinical studies use different endpoints, depending on the main organ involvement studied [5]. However, patient-reported outcomes are routinely measured in clinical trials and often implemented as secondary endpoints. The World Association of Sarcoidosis and Other Granulomatous Disorders, therefore, recommends that sarcoidosis studies should include multiple endpoints gauging an ameliorated organ-specific physiology and improved quality of life [5].

King’s Sarcoidosis Questionnaire (KSQ) is a novel, validated, health-related quality of life (HRQOL) questionnaire on sarcoidosis covering five domains (general health status (GHS), medications (M), lung (L), eye (E) and skin (S)) [6]. The KSQ has already been translated into Dutch and validated in a Dutch cohort [7]. It is in use in American (clinical trials identifier: NCT02024555), British (NCT02643732) and Dutch (Netherlands trial register: NTR4328) clinical trials on sarcoidosis. For future multinational observational and interventional studies on sarcoidosis, a validated German version of the KSQ is needed. Hence, we translated the KSQ into German and aimed to validate it in a German cohort of patients with sarcoidosis.

Methods
Translation
The English version of the KSQ was used for translation into German and validation in a German cohort [6]. A multistep, forward-backward approach was chosen [8]: First, the English version of the KSQ was independently translated by three authors (EF, JMQ, JCS), merged to a preliminary version, then backward translated by a native speaker. After implementing small suggestions by the original author (SSB), this German pilot version was tested in structured interviews of ten patients with sarcoidosis. Final modifications were implemented and documented based on the structured interviews.

Subjects
In the outpatient clinic of the department of pneumology, University Hospital Freiburg, consecutive adult, fluent German-speaking patients were screened as to whether they had been diagnosed with sarcoidosis according to the consensus statement of three scientific societies (ERS, ATS, WASOG) [1]. Over a one-year period, 194 patients with sarcoidosis were included in this study after obtaining their informed consent (see Table 1).

Study procedure
All participants self-completed the following questionnaires and measurements: the KSQ, the Short Form Health Survey (SF-36) [9], the Borg dyspnea scale (CR-10) [10] and the visual analogue scale for dyspnea (VAS-D) [11]. Furthermore, all patients were asked to answer structured questions on their nationality (country of citizenship), sex, duration of the sarcoidosis, sick-days per year, highest educational certificate, employment, and family status.

Statistical analysis
Our approach is oriented on the original publication of the KSQ (6) and on modern patient-reported outcomes methodology as described in [12]. We have

| Table 1 Sample Characteristics |
|-------------------------------|
| Variable | N = 194 |
| Age M and SD | 52.95 (12.74) |
| Gender N (%) | |
| Female | 93 (47.9) |
| Male | 100 (51.5) |
| Nationality N (%) | |
| German | 175 (90.2) |
| Other | 14 (7.2) |
| Partnership N (%) | |
| Yes | 147 (75.8) |
| No | 38 (19.6) |
| Level of education N (%) | |
| Elementary school | 56 (28.9) |
| Secondary school | 64 (33.0) |
| Polytechnic secondary school | 2 (1.0) |
| Technical college qualification | 14 (7.2) |
| University qualification | 44 (22.7) |
| Other or no certificate | 7 (3.6) |
| Employment status N (%) | |
| Employed | 118 (60.8) |
| Not employed (e.g., retired, housewife or –husband) | 59 (30.4) |
| Duration of illness N (%) | |
| < 1 year | 11 (5.7) |
| 1–2 years | 20 (10.3) |
| 3–5 years | 60 (30.9) |
| 6–10 years | 47 (24.2) |
| > 10 years | 41 (21.1) |

Note: Totals not adding up to N = 194 are the result of missing values.
N numbers, M mean score, SD standard deviation. The percentages refer to the raw values including missing values.
adopted the interpretation of psychometric values of Terwee et al. [13].

**Distribution properties**
To give descriptive information and distribution properties, non-response, item difficulty, skewness and kurtosis were computed (Additional file 1: Table S1). Items with ceiling or floor effects (exceeding 50% of values in the extreme categories) were determined. On the scale-value level, we considered more than 15% of values in the extreme categories as an indicator for ceiling or floor effects.

**Exploratory factor analysis (EFA)**
We conducted an EFA (software: IBM SPSS version 24, principal component analysis with oblique rotation). To determine the number of factors to be extracted, the following criteria were used: (a) factor loading (an item was removed if it did not load unambiguously on the extracted factors, factor loading $\geq 0.50$ on exactly one factor; factor loading $< 0.40$ on all other factors), and (b) congruence with the original KSQ.

**Item response theory (IRT) analyses**
We used the 1-parameter IRT model (Rasch model) for item response theory analyses (software: WINSTEPS version 3.68), as it is an effective tool for clinical applications [14]. It also provides stable parameter estimates for even small case numbers [15]. Every KSQ scale was analyzed separately. Infit and outfit mean square statistics (Infit MNSQ, Outfit MNSQ) were used as goodness-of-fit statistics. Poor item fit was defined as an infit or outfit $< 0.6$ or $> 1.4$ [16]. Items with a poor infit or outfit were eliminated. The Person Separation Index (PSEP) was computed to assess the KSQ’s ability to discriminate patients with different levels of impairments. The PSEP was used as an indicator of the fit statistics’ reliability. Reliability of 0.8 is achieved for PSEP $> 2$, and reliability of 0.90 for PSEP $> 3$.

**Confirmatory factor analysis**
Based on the EFA factor solution and results of the Rasch model, we conducted a confirmatory factor analyses (CFA) using IBM SPSS AMOS 24 software. A five-factor model (corresponding with the KSQ’s five scales) was tested. Model fit was evaluated using the Comparative Fit Index (CFI, [17]), Tucker–Lewis index (TLI, [18]), root mean square error of approximation (RMSEA) and standardized root mean square residual (SRMR). CFI and TLI values $> 0.90$ are an indication of good fit. RMSEA values $< 0.10$ suggest a moderate fit; values $< 0.05$ a good fit [17]. The SRMR value should be under 0.08 [17]. Satisfactory model fit is assumed whenever at least three out of four parameters produce good values [19]. If model fit was low, a bifactor model was computed to test if a model with a general factor and five group factors (corresponding to the KSQ scales) would better account for our data.

**Internal consistency**
Cronbach’s Alpha was calculated. Values between 0.75 and 0.95 are considered good. The item-total correlation should be between 0.20 and 0.80.

**Construct validity**
To evaluate construct validity, we tested the hypotheses below.

1) As the Borg scale and VAS Dyspnea assess lung symptoms, we expect these parameters to correlate closely ($r \geq 0.60$) with the KSQ Lung scale, and we expect low or moderate correlations ($0.20$–$0.60$) with the other KSQ scales.

2) We expect high correlations ($r \geq 0.60$) between the KSQ General Health scale and the SF-36 Physical and Mental Component scales, as those scales measure two facets of general health status. The correlations between the SF-36 Physical and Mental Component scales and other KSQ scales are assumed to be low or moderate.

**Results**

**Structured interviews**
Ten patients with sarcoidosis answered the pilot German KSQ in structured interviews. The sarcoid patients had no problems understanding or answering the questionnaire. To improve comprehensibility, minor modifications were made in the final German KSQ. The final version is presented in Additional file 1: Table S1.

**Step 1: development of an optimized German version allowing item selection**

**Distribution properties**
Eight items show floor effects (1 item on the General Health Status Scale, 2 items on the Lung, Medication and Skin scale, respectively, and 1 item on the Eyes scale). The 3 medication items reveal a high non-response rate up to 11.3%. The latter result presumably reflects the fact that some patients take no medicine. On the scale-value level, we observed floor effects in conjunction with the Medication, Skin, and Eyes scales. 161 of 194 patients (83.0%) answered all items. If the Medication Scale is disregarded, 176 persons filled in all questions (90.7%).

**Exploratory factor analysis**
The Lung, Medication, Skin, and Eyes scales were reproduced exactly as in the original KSQ (Additional file 2: Farin et al. Health and Quality of Life Outcomes (2019) 17:62 Page 3 of 7
Table S2). As four items on the “General Health Status” scale (items 6 to 9) exhibited ambiguous factor loadings, we decided to eliminate them.

**Item response theory (IRT) analyses**
To ensure fit to the Rasch model, items were recoded using a five-point Likert scale. Response categories 2 and 3 (most of the time or a good bit of the time) as well as 5 and 6 (a little of the time vs. hardly any of the time) were merged. Item 11 (“My cough has caused me pain/discomfort”) was eliminated, as the infit and outfit values exceeded the acceptable cut-offs.

After making those changes, all the scales’ fit values fell in the adequate range (General Health Status Scale GHS 0.71–1.37, Lung Scale 0.80–1.35, Medication Scale 0.74–1.35, Skin Scale 0.73–1.17, Eyes Scale 0.80–1.27). The PSEP reveals good values for the scales GHS (2.96), Lung (2.34), and Eyes (2.38). For the scales with only 3 items (Medication and Skin), the values are below 2.

**Confirmatory factor analysis**
Table 2 presents the CFA results. The original CFA model (without items 6, 7, 8, 9, 11) demonstrated an unsatisfactory fit. The bifactor model does not lead to a better fit. As modification indices suggested that model fit would improve provided correlated error terms were included, we added three theoretically plausible correlated error terms. The first three items on the Eyes scale (dry eyes, red eyes, difficulty with bright lights) exhibit similar content and seem to possess a joint component (My chest has felt tight, I have had episodes of breathlessness). Here, too, the items’ contents resemble each other more than those in the total scale, which addresses different symptoms such as coughing. The modified CFA model with correlated error terms displays a good model fit (Table 2).

**Internal consistency**
Table 3 presents internal consistency values based on the KSQ German version with 24 items. Cronbach’s Alpha values are good; the item-total correlation falls within the acceptable range for all scales.

**Construct validity**
Hypothesis 1 is confirmed (see Table 4). The correlation between the KSQ Lung scale and Borg Scale and VAS Dyspnea is −.64 and −.67. The other KSQ scales’ correlations with the Borg Scale and VAS Dyspnea are in the −.23 to −.44 range.

Hypothesis 2 is only partly confirmed. The correlation between the KSQ General Health scale and SF-36 Mental Component is high (r = .63), as expected, but the correlation with the Physical Component is only moderate (r = .47). The correlations between the SF-36 Physical and Mental Component scales and other KSQ scales are low to moderate with the exception of the association between the SF-36 Physical Component and KSQ Lung scale (r = .67).

**Step 2: psychometric properties of the unmodified German version**
To compare the properties of our optimized 24-item version with those of the original version (and thereby expose advantages and disadvantages), we illustrate the psychometric properties of the 29-item German version in a shortened format. Additional file 3: Table S3 and Additional file 4: Table S4 present Cronbach’s Alpha values and construct validity hypothesis testing with this version. The General Health Status Scale’s mean inter-item correlation is lower in the original version, but Cronbach’s Alpha is nearly the same for all scales. As with the Rasch-scaled version, construct validity hypothesis 1 is confirmed and hypothesis 2 is only partly confirmed (the association between the SF-36 Physical Component and KSQ Lung scale is inappropriately high, r = .70). But with the original version, the correlation between KSQ General Health scale and SF-36 Physical Component falls within the expected range (r = 0.60). Confirmatory factor analysis reveals an unsatisfactory fit (TLI = 0.82, CFI = 0.84, RMSEA = 0.09, SRMR = 0.07). Our Rasch analyses showed that the infit and outfit values of 5 items fell outside the acceptable range.

**Discussion**
The psychometric properties of the German KSQ (modified version with 24 items) are good. We provide evidence of reliability, Rasch model fit, and internal consistency as well as structural and construct validity. Concerning the Lung, Skin, Eye and Medication scales,

| Table 2 Global Fit Indices of Confirmatory Factor Analyses (24 item version) |
|---------------------------------------------------------------|
| TLI | CFI | RMSEA | RMSEA 90% CI | SRMR |
|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
| Only scale factors: original model | 0.86 | 0.87 | 0.10 | 0.09–0.10 | 0.07 |
| Bifactor model (unmodified) | 0.86 | 0.89 | 0.09 | 0.08–0.10 | 0.14 |
| Only scale factors: Modified model | 0.90 | 0.91 | 0.08 | 0.07–0.09 | 0.07 |

Abbreviations: TLI Tucker–Lewis index, CFI comparative fit index, RMSEA root mean square error of approximation, SRMR standardized root mean square residual
there is perfect correspondence between the original English and German versions. However, the KSQ’s General Health Status scale could not be replicated. In the EFA, the factor loadings of four items on that scale are below 0.30. A confirmatory test of the scale’s unidimensionality with structural equation modeling (data not shown in the results section) demonstrates a poor model fit (with all fit indices exceeding the acceptable range). The items omitted assess worries and embarrassment as well as pain; the remaining items primarily assess fatigue as well as anxiety and depressive symptoms. Considering the general health status of sarcoidosis patients as a unidimensional concept appears to be difficult. This is not surprising, as these patients’ impairments and complaints are heterogeneous and complex. Interestingly, neither the KSQ’s original publication (6), nor studies addressing KSQ translations in other languages (7), have reported data on unidimensionality and structural validity.

Considering that the German version of the KSQ General Health Status scale focuses on fatigue, anxiety, and depression, its use is justified. But if one intends to capture a broad perspective of health status impairments in sarcoidosis patients, it may be advisable to use other well-established instruments that assess patients’ psycho-social problems such as worries, coping deficits, and pain.

Disregarding the problems we encountered with the general health status scale, the German KSQ’s psychometric properties (internal consistency, fit to the Rasch model, indication of construct validity) resemble the original version’s. However, to ensure Rasch model fit, we had to merge two response categories, reducing the 7-point Likert scale to a 5-point scale. It remains unclear whether this is due to the limited ability of patients to distinguish different levels of symptom severity or to a translation artefact (reflecting the difficulties finding conceptual equivalents to the English response choices (see the Discussion in [20]).

As some users may emphasize comparability with international data, we analyzed the original German KSQ’s properties with 29 items and the 7-point Likert scale. The measurement properties of the original unmodified version are similar in their construct validity and internal consistency; however, we were unable to confirm structural validity and fit to the Rasch model. Thus the 24-item version’s advantages over the original 29-item version result from their factorial validity and fit to the Rasch model.

The strengths of this study are the use of modern patient-reported outcomes methodology, including item response modeling and confirmatory factor analyses. But there are some limitations; we have no data on test-retest-reliability, and we did not validate our modified German KSQ in an independent cohort. Further validity testing employing physiological parameters of pulmonary function and proving associations between KSQ scales and apparatus measures is pending. Our sample size suffices for our statistical analyses, but referring to rules of thumb concerning sample sizes in exploratory

Table 3 Internal Consistency

| Scale and items                  | N   | Items | Item-Total correlation | Mean Inter-Item correlation | Cronbach’s alpha |
|----------------------------------|-----|-------|------------------------|----------------------------|------------------|
| General Health Status            | 186 | 6     | 0.59–0.81              | 0.60                       | 0.90             |
| Includes items 01, 02, 03, 04, 05 and 10 |     |       |                        |                            |                  |
| Lung                             | 189 | 5     | 0.65–0.78              | 0.64                       | 0.90             |
| Includes items 12, 13, 14, 15 and 16 |     |       |                        |                            |                  |
| Medication                       | 172 | 3     | 0.58–0.77              | 0.62                       | 0.82             |
| Includes items 17, 18 and 19     |     |       |                        |                            |                  |
| Skin                             | 192 | 3     | 0.67–0.73              | 0.63                       | 0.83             |
| Includes items 20, 21 and 22     |     |       |                        |                            |                  |
| Eyes                             | 187 | 7     | 0.68–0.79              | 0.59                       | 0.91             |
| Includes items 23, 24, 25, 26, 27, 28 and 29 |     |       |                        |                            |                  |

Table 4 Concurrent Validity

| Kings Sarcoidosis Questionnaire | General Health Status | Lung | Medication | Skin | Eyes |
|---------------------------------|-----------------------|------|------------|------|------|
| SF-36 Physical Component Score  | .47                   | .67  | .28        | .30  | .37  |
| SF-36 Mental Component Score    | .63                   | .27  | .32        | .26* | .21* |
| Borg scale                      | −.44                  | −.64 | −.39       | −.30 | −.38 |
| VAS Dyspnoea                    | −.35                  | −.67 | −.33       | −.23*| −.27 |

Notes: For construct validity analysis, estimated person measures for KSQ scales as calculated in Rasch-analysis were used. Pearson’s correlations, all p < 0.001 except * p < .01. Interpretation guide: KSQ scales: high values = low burden, SF-36 scales: high values = high manifestation of related dimensions’ content, Borg scale: high values = high dyspnoea, VAS Dyspnoea: high values = high dyspnoea. Correlations that confirm the hypothesized relationships are marked in bold.
factor analyses (e.g. the rule of 10: there should be at least 10 persons for each item in the instrument being used [21]); several more individuals would have been favorable. The majority of our analyses included only persons with values on all scales, so sarcoidosis patients without medication (about 10%) were mostly omitted. Furthermore, 76.2% of the patients had an illness lasting 3 years or more, thus most of our patients suffer from chronic sarcoidosis, leading to less explanatory power from patients with acute sarcoidosis. Future analyses of the KSQ’s German version should address differential item functioning (DIF), i.e., DIF by language (English versus German).

Conclusion
Taken together, we were able to translate and validate the German KSQ and report good psychometric properties in a reduced 24-item version. This modified version has the advantage that all scales are unidimensional and fulfill the Rasch model’s requirements, ensuring its benefits such as sample invariance, convenient handling of missing values, and good clinical interpretability, as person and item parameters are scaled within the same dimension. The original 29-item version, on the other hand, enables us to compare German data with international data, as the KSQ has been translated into over 10 languages. The German KSQ’s potential applications are manifold. First, it could be used to monitor sarcoidosis patients during routine check-ups, as it is quick to fill out. Second, the German KSQ (29-item version) enables German cohorts to participate in multinational clinical sarcoidosis trials employing KSQ. Third, the German KSQ provides clinical researchers with a tool to study the influence of objectifiable sarcoidosis disease activity and organ impairment on the disease’s perception and symptoms.

Additional files

**Additional file 1:** Items Analysis: German version of the Kings Sarcoidosis Questionnaire. (DOCX 51 kb)

**Additional file 2:** Exploratory Factor Analysis: German version of the Kings Sarcoidosis Questionnaire. (DOCX 46 kb)

**Additional file 3:** Internal Consistency of the original version (29 items, seven-point Likert scale). (DOCX 35 kb)

**Additional file 4:** Concurrent Validity of the original version (29 items, seven-point Likert scale). (DOCX 35 kb)

**Abbreviations**
CFA: Confirmatory factor analysis; CFI: Comparative Fit Index; EFA: Exploratory factor analysis; KSQ: King’s Sarcoidosis Questionnaire; RMSEA: Root mean square error of approximation; SRMR: Standardized root mean square residual; TLI: Tucker–Lewis index.

**Acknowledgments**
Foremost, we thank every participant of this study, as it would have been impossible without them. We thank Nicole Wehle for her structured interviews, Oliver Buchholz for his digitization of the questionnaires, Carole Curten for her back-translation into English, Carole Curten and Susan Ardito for proof reading. Furthermore, we thank Renate Braune, Dr. rer. Nat. Bernd Quadderr and Doris Eistele of the German sarcoidosis self-help association (Deutsche Sarkoidose-Vereinigung) for their generous support in recruiting the cohort.

**Funding**
Intra mural funding.

**Availability of data and materials**
Supporting data can be accessed by the corresponding author.

**Authors’ contributions**
EF, JMQ and JCS conceived of, designed and coordinated the study. The KSQ was translated by EF, JMQ and JCS. After back-translation, SSB compared it to his original KSQ and gave suggestions for the final German KSQ. JMQ and JCS obtained a positive vote by the Ethics Committee. BCF, JMQ and JCS recruited the participants. KH and EF performed the statistical analysis. EF, KH and JCS drafted the manuscript. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**
We obtained a positive vote from the Ethics Committee of the University of Freiburg prior to initiating this study. Only patients providing informed consent were included in the study.

**Consent for publication**
Not applicable.

**Competing interests**
The authors declare that they have no competing interests.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**
1. Section of Health Care Research and Rehabilitation Research, Faculty of Medicine, Medical Center- University of Freiburg, Freiburg, Germany.
2. Department of Pneumology, Faculty of Medicine, Medical Center- University of Freiburg, Freiburg, Germany.
3. Division of Asthma, Allergy and Lung Biology, King’s College London, London, London, UK.
4. Section of Pulmonary, Critical Care and Sleep Medicine, Yale University School of Medicine, New Haven, CT, USA.

Received: 16 January 2018 Accepted: 28 March 2019
Published online: 11 April 2019

**References**
1. Statement on sarcoidosis. Joint statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the world Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of directors and by the ER. Am J Respir Crit Care Med. 1999;160:736–55.
2. Valeyre D, Prasse A, Nunes H, Uznuny H, Brielle P-Y, Müller-Queheim J. Sarcoidosis. Lancet. 2014;383:1155–67.
3. Cox CE, Donohue JF, Brown CD, Kataria YP, Judson MA. Health-related quality of life of persons with sarcoidosis. Chest. 2004;125:997–1004.
4. Drent M, Wirnsberger RM, Breteler MH, Kock LM, de Vries J, Wouters EF. Quality of life and depressive symptoms in patients suffering from sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis Off J WASOG. 1998;15:59–66.
5. Baughman RP, Drent M, Culver DA, Grutters JC, Handa T, Humbert M, et al. Endpoints for clinical trials of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis Off J WASOG World Assoc Sarcoidosis Granulomatous Disord. 2012;29:90–8.
6. Patel AS, Siegert RJ, Creamer D, Larkin G, Maher TM, Renzoni EA, et al. The development and validation of the King’s sarcoidosis questionnaire for the assessment of health status. Thorax. 2013;68:57–65.
7. van Manen MJG, Vapaenaa M, Stockpape B, Drent M, Efferich M, de VJ, et al. Validation of the King’s sarcoidosis questionnaire (KSQ) in a Dutch sarcoidosis population. Sarcoidosis Vasc Diffuse Lung Dis. 2016;33:75–82.
8. Acquadro C, Conway K, Hareendran A, Aaronson N. Literature review of methods to translate health-related quality of life questionnaires for use in multinational clinical trials. Value Health. 2008;11:509–21.

9. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473–83.

10. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982;14:377–81.

11. Atkison RC. Measurement of feelings using visual analogue scales. Proc R Soc Med. 1969;62:989–93.

12. Amtmann D, Cook RF, Jensen MP, Chen W-H, Chol S, Revicki D, et al. Development of a PROMIS item bank to measure pain interference. Pain. 2010;150:17–82.

13. Terwee CB, Bot SD, de Boer MR, van der Windt DA, Knol DL, Dekker J, Bouter LM, de Vet HC. Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol. 2007;60(1):34–42.

14. Coster WJ, Haley SM, Andres PL, Ludlow LH, Bond TLY, Ni P. Refining the conceptual basis for rehabilitation outcome measurement: personal care and instrumental activities domain. Med Care. 2004;42(Supplement):I-62.

15. Conrad KJ, Smith EV. International conference on objective measurement: applications of Rasch analysis in health care. Med Care. 2004;42(Supplement):I-1.

16. Bond T, Fox CM. Applying the Rasch model: fundamental measurement in the human sciences, Third Edition. Hoboken: Taylor and Francis; 2015.

17. Hu L, Bentler PM. Cutoff criteria for fit indexes in covariance structure analysis: conventional criteria versus new alternatives. Struct Equ Model Multidiscip J. 1999;6:1–55.

18. Tucker LR, Lewis C. A reliability coefficient for maximum likelihood factor analysis. Psychometrika. 1973;38:1–10.

19. Farin E, Ullrich A, Hauer J. Participation and social functioning in patients with fibromyalgia: development and testing of a new questionnaire. Health Qual Life Outcomes. 2013;11:135.

20. Birring S, Fletcher H, Tully T, Patel A, Kullberg S, Modulkoc N, et al. Standardised translation of the King’s sarcoidosis questionnaire (KSQ) into eleven languages. Am J Respir Crit Care Med. 2017:A4759.

21. Nunnally JC, Bernstein IH. Psychometric theory. 3rd ed. New York: McGraw-Hill; 1978.